Australia markets close in 3 minutes

Spyre Therapeutics, Inc. (SYRE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
22.71-0.68 (-2.91%)
At close: 04:00PM EDT
22.77 +0.06 (+0.26%)
After hours: 04:13PM EDT
Show:
Income statement
Balance sheet
Annual

Cash flow

All numbers in thousands
Breakdown
ttm
31/12/2023
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Cash flows from operating activities
Net income
-364,225
-338,790
-83,815
-65,801
-80,893
-
Depreciation & amortisation
196
744
1,567
1,576
996
-
Stock-based compensation
37,801
25,675
7,111
8,038
6,256
-
Change in working capital
-369
-5,206
-5,503
1,833
-2,540
-
Accounts payable
1,044
218
-2,641
1,065
-544
-
Other working capital
-110,818
-99,910
-80,182
-54,289
-80,055
-
Other non-cash items
3,200
2,772
823
90
619
-
Net cash provided by operating activities
-110,818
-99,910
-80,144
-53,716
-75,775
-
Cash flows from investing activities
Investments in property, plant and equipment
-
-
-38
-573
-4,280
-1,492
Purchases of investments
-319,516
-166,803
-39,500
-133,079
-129,000
-
Sales/maturities of investments
69,900
39,900
96,546
111,033
125,676
-
Net cash used for investing activities
-231,106
-108,393
57,008
-22,619
-7,604
-
Cash flows from financing activities
Debt repayment
-8
-16
-418
-510
-20
-
Common stock issued
-
169,110
42,874
0
153,716
-
Other financing activities
-
-5,786
-
-
-
-
Net cash used provided by (used for) financing activities
533,232
361,077
42,678
1,393
154,512
-
Net change in cash
191,318
152,799
19,436
-74,957
71,184
-
Cash at beginning of period
36,553
36,416
16,980
91,937
20,753
-
Cash at end of period
227,861
189,215
36,416
16,980
91,937
-
Free cash flow
Operating cash flow
-110,818
-99,910
-80,144
-53,716
-75,775
-
Capital expenditure
-
-
-38
-573
-4,280
-1,492
Free cash flow
-110,818
-99,910
-80,182
-54,289
-80,055
-